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Abstract
Introduction To aid the development of better algorithms for 1 H NMR data analysis, such as alignment or peak-fitting, it is 
important to characterise and model chemical shift changes caused by variation in pH. The number of protonation sites, a 
key parameter in the theoretical relationship between pH and chemical shift, is traditionally estimated from the molecular 
structure, which is often unknown in untargeted metabolomics applications.
Objective We aim to use observed NMR chemical shift titration data to estimate the number of protonation sites for a range 
of urinary metabolites.
Methods A pool of urine from healthy subjects was titrated in the range pH 2–12, standard 1 H NMR spectra were acquired 
and positions of 51 peaks (corresponding to 32 identified metabolites) were recorded. A theoretical model of chemical shift 
was fit to the data using a Bayesian statistical framework, using model selection procedures in a Markov Chain Monte Carlo 
algorithm to estimate the number of protonation sites for each molecule.
Results The estimated number of protonation sites was found to be correct for 41 out of 51 peaks. In some cases, the number 
of sites was incorrectly estimated, due to very close pKa values or a limited amount of data in the required pH range.
Conclusions Given appropriate data, it is possible to estimate the number of protonation sites for many metabolites typically 
observed in 1 H NMR metabolomics without knowledge of the molecular structure. This approach may be a valuable resource 
for the development of future automated metabolite alignment, annotation and peak fitting algorithms.
Keywords NMR · pH · Peak shift changes · Protonation site · Bayesian model selection
1 Introduction
1 H NMR is an important technique in metabolomics as it 
provides highly reproducible, quantitative information on a 
wide variety of metabolites. The chemical shift and multi-
plicity pattern are characteristic of the metabolite’s chemical 
structure, but are complicated by small sample-to-sample 
changes in the position of individual resonances due to 
changes in pH, ionic strength or other physical parameters 
of the matrix (Fan 1996). While these can be ameliorated to 
some degree by careful analytical procedures, such as addi-
tion of buffers and control of physical conditions, changes 
in chemical shifts are still present in most NMR metabo-
lomic data sets. Computational approaches to correct these 
changes, such as alignment, can introduce artefacts and are 
not able to correct shift changes which swap the ordering of 
resonances (Vu and Laukens 2013). Chemical shift changes 
can become a major problem in the statistical analysis of 
NMR metabolomics data, as they disrupt the linear relation-
ship between NMR intensity at a given position and metabo-
lite abundance (Ebbels and Cavill 2009). Thus it becomes 
important to characterise and model chemical shift changes 
(see e.g. Takis et al. 2017), in part to aid construction of bet-
ter algorithms for data analysis, such as alignment or peak-
fitting. We recently reported titration model parameters such 
as acid/base limits and pKas for 33 identified metabolites 
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in human urine, as well as titration curves for a further 65 
unidentified peaks (Tredwell et al. 2016). A key problem 
in modelling NMR spectra from untargeted metabolomics 
is the unknown structure of the molecules giving rise to 
each resonance, and thus the lack of knowledge of important 
parameters. In particular, the number of proton binding sites 
strongly influences relationship of chemical shift to pH, but 
has traditionally been hard to infer from titration data alone. 
Here, we report the successful development and application 
of a Bayesian approach to estimating the number of proton 
binding sites in 1 H NMR metabolomics data, without knowl-
edge of the molecule’s chemical structure.
2  Methods
2.1  The model
As protonation is usually rapid and reversible on the NMR 
timescale, the theoretical chemical shift ( ̃𝛿 ) is a weighted 
average of the limiting chemical shifts of the unprotonated 
( 훿A ) and the protonated ( 훿HA ) states of the molecule (Acker-
man et al. 1996; Szakács et al. 2004). Ackerman et al. (1996) 
model the theoretical chemical shift as a function of pH and 
pKa as follows
Szakács et al. (2004) extend this approach to molecules with 
q > 1 protonation sites:
accounting for the interaction between protons bound at dif-
ferent binding sites and the statistics of proton binding.
From Eqs. (1, 2), it is evident that the theoretical chemical 
shift follows a titration curve which describes the position 
of the resonance over a range of pH. When the number of 
sites is known, nonlinear fitting can be applied using Eq. 
(2) to model the titration curve to obtain the pKa values, 
as well as the acid and base chemical shift limits (Tredwell 
et al. 2016). However, in many metabolomics applications 
(for example alignment), the number of protonation sites 
may not be known, especially for unknowns or molecules of 
complex structure. Thus it is of interest to consider whether 
the number of protonation sites can be estimated along with 
the pH dependence of the chemical shift.
Here, we focus on inferring the number of protonation 
sites from observations of chemical shift changes for a given 
resonance at different pH values. Due to their small size, few 























metabolites have many protonation sites. We therefore limit 
the search space to 1-site, 2-site and 3-site models, although 
the approach can be easily extended to include more than 
3 protonation sites if required. We employ a Bayesian 
approach because it provides a natural way of incorporating 
prior information and combining results of different experi-
ments. In the Bayesian framework, it is, in principle, easy 
to incorporate model choice in the inferential process by 
specifying an appropriate prior distribution on the model 
space. Posterior inference is performed through Markov 
chain Monte Carlo (MCMC) methods. In this context, as 
model selection involves models with different dimensions, 
we employ a Reversible jump MCMC algorithm, which is 
implemented in the software JAGS (Plummer and Martyn 
2003).
We propose a non-linear Bayesian regression model for 
each NMR resonance for each molecule. In particular, we 
assume that the observed chemical shift, yi , follows a nor-
mal distribution, with mean 𝛿 , representing the theoretical 
chemical shift, and variance 휎2 , the measurement error:
The theoretical chemical shift 𝛿i is a function of the pH, 
pKa, 훿A and the number of protonation sites as described 
in Eq. (2).
2.2  Specification of prior knowledge
Since most metabolites have up to three protonation sites, 
we specify as prior distribution on the number of protonation 
sites a uniform distribution on the set {1, 2, 3} . Therefore, 
each model is a priori equally likely. We complete the model 
by specifying a prior distribution on the remaining param-
eters. Assuming no additional spectral effects and condition-
ing on the number of sites q, we choose a uniform distribu-
tion defined over the NMR ppm scale [0, 10] as prior for 훿A 
and 훿HjA, j = 1,… , q.
Moreover, to improve efficiency in searching the param-
eter space and avoid identifiability issues (where different 
combinations of parameter values lead to the same likeli-
hood value so that the model is not able to distinguish 
between them) we impose an order constraint on the 훅퐀 and 
훅퐇퐣퐀 values, in descending or ascending order according to 
the trend of the data. This improves MCMC convergence 
and the accuracy of estimation. The order direction can be 
estimated, for example, by fitting a simple linear regression, 
퐲 = 훽퐩퐇 + b , to the data and considering the sign of the 
estimated slope parameter 훽 . If 𝛽 > 0 , the relationship 
between chemical shift and pH is approximately increasing 
a n d  w e  w o u l d  i m p o s e  t h e  c o n s t r a i n t 
𝛿A > 𝛿H1A > 𝛿H2A >⋯ > 𝛿HqA on the parameter space. On 
yi|𝛿i, 𝜎2 ∼ N(𝛿, 𝜎2)
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the other hand, if 𝛽 < 0 , we would impose restriction 
𝛿A < 𝛿H1A < 𝛿H2A <⋯ < 𝛿HqA.
For most metabolites the change in chemical shift 
between adjacent protonation sites is smaller than 1ppm 
and the total shift change from most acidic to most basic 
peak position is also smaller than 1ppm. This allows us to 
assume that the change of chemical shift between adjacent 
protonation sites is smaller than 1ppm, i.e.
Finally, an Inverse-Gamma prior distribution with param-
eters ( a2, a ), which is often used as a Bayesian prior for 
error variance, is chosen for 휎2 . Note that a, which reflects 
the measurement error, should be chosen carefully according 
to the experiment. In our model, a = 104 is chosen based on 
empirical estimation of the measurement error related to the 
resolution of the spectrometer and its ability to measure peak 
position (Karakach et al. 2009).
We fit the model to each resonance independently. We 
pick as an estimate of q the number of protonation sites 
with highest posterior probability. We then refit the same 
model but fix q equal to its posterior estimate to obtain an 
estimate of the other parameters conditional on q. Posterior 
inference is performed in JAGS, running four chains of the 
MCMC algorithm for 50,000 iterations with a burn-in period 
of 25,000.
2.3  Prior specification for pKa
A great advantage of working in a Bayesian framework is 
the ability of the model to incorporate problem specific 
prior information. To assign informative prior knowledge 
on the pKa range, which aids computational stability and 
improves convergence of the MCMC algorithm, we exploit 
information available in the the Human Metabolome Data-
base (version 4.0), which records the pKa values of many 
common urine metabolites.
By studying the empirical distribution of the pKa val-
ues downloaded from the database, we found that the dis-
tribution of pKa values has a heavy right tail. We choose 
as prior range for pKa [1.2, 13.7] to correspond to the pH 
range of our data. This range includes most urine metabo-
lites reported in HMDB, but excludes values below the 7% 
and above the 90% percentile of the pKa distribution.
2.4  Data
Details of sample collection, NMR acquisition and data pro-
cessing can be found in Tredwell et al. (2016). All data used 
in this study is publically available as Supplementary mate-
rial to the original article under the Creative Commons attri-
bution 4.0 International License https ://creat iveco mmons 
0 < |𝛿A − 𝛿H1A| < 1 0 < |𝛿HjA − 𝛿Hj+1A| < 1, j = 1, 2, 3, ...
.org/licen ses/by/4.0/. Briefly, a urine sample was collected 
from five different individuals and pooled to obtain an aver-
age representative human urine sample. To avoid chemi-
cal shift effects from metal ions the urine was treated with 
chelex resin to reduce both Ca2+ and Mg2+ concentrations 
without significantly altering metabolite composition. Note 
that, while this results in non-physiological concentrations 
of these ions, it is not expected to affect the ability of the 
model to recover the number of protonation sites. The pool 
was then titrated to produce 51 samples covering the range 
2 < 횙홷 < 12 . Spectra were acquired on a Bruker Avance 
DRX600 NMR spectrometer (Bruker BioSpin, Rheinstetten, 
Germany), with a 1 H frequency of 600 MHz. A one-dimen-
sional NOESY sequence was used with water suppression, 
and data were acquired into 64k data points over a spectral 
width of 12 KHz, with eight dummy scans and 64 scans per 
sample. Spectra were processed in iNMR 3.4 (Nucleomat-
ica, Molfetta, Italy). Fourier transform of the free-induction 
decay was applied with a line broadening of 0.5 Hz. Spectra 
were manually phased and automated first order baseline 
correction was applied. Metabolites were assigned using 
the Chenomx NMR Suite 5.1 (Chenomx, Inc., Edmonton, 
Alberta, Canada) relative to 4,4-dimethyl-4-silapentane-
1-sulfonic acid (DSS) as an internal standard. Metabolite 
peak positions were obtained using in-house MATLAB 
scripts. Data for one metabolite (phenylalanine at 7.35 and 
7.41 ppm) were discarded as it was found that the peak posi-
tions could not be measured accurately due to the high level 
of peak overlap in this region of the spectra.
3  Results and discussion
Our aim is to estimate the number of protonation sites for 
small molecule metabolites from their observed NMR pH 
titration curves. From Fig. 1, it is clear that when the number 
of protonation sites is estimated correctly, the chemical shift 
changes match the data quite well.
A summary of the results is shown in Table 1. More 
detailed results for each resonance can be found in Table 2. 
Of the 51 resonances, the estimated number of sites matches 
that found in the literature in 41 cases ( 80.4% ). It is evident 
that most of the incorrect predictions (10 out of 51) result 
from an underestimation of the number of sites compared to 
the literature value. The literature site numbers are sourced 
from handbook of biochemistry and molecular biology 
(Lundblad and Macdonald 2010). Where this was not pos-
sible, (hydroxyisobutyrate, hydroxyisovalerate, indoxyl and 
methyl-2-oxovalerate) the number was determined from an 
assessment of the molecular structure.
Given the estimation of the number of protonation sites, 
the other parameters of the model (acid limits, base limits 
and pKa values) can be estimated using the same model. 
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The modelled pKa values closely agree with the literature 
values (Lundblad and Macdonald 2010), and the modelled 
acid and base limits are also in good agreement with the 
previously modelled values (Tredwell et al. 2016). There-
fore we do not present these in detail here. Four examples 
including 1, 2 and 3 protonation sites, (acetate, alanine, 
threonine and TTMethylHistidine) are shown in Table 3 
and Fig. 2.
3.1  Metabolites with incorrectly estimated number 
of protonation sites
The model failed to estimate the correct number of protona-
tion sites for 10 out of 51 resonances. There are several types 
of problem leading to incorrect estimation of the number 
of protonation sites. The first type ocurrs when at least one 
literature pKa value lies outside the range of the observed 
data. Taurine is a good example of this, as shown in Fig. 3, 
where it can be seen that one pKa lies at pH 1.5, while the 
data only cover the pH range 3.2–12.
The second type of inaccurate estimation happens when 
two adjacent pKas are so close that the change in chemical 
shift between them is too small compared to the measure-
ment error. The 훿 2.7 resonance of citrate is a good example 
of this, as in Fig. 3, where the smooth titration curve around 
pH 4–5 does not suggest the presence of the third pKa at 
Fig. 1  Upper panel: 1 H NMR spectra with pH adjusted from 2 to 12. Lower left panel: observed chemical shift positions of 51 resonances. 
Lower right panel: fitted chemical shift positions for the 51 resonances. Only resonances with correct predictions are shown
Table 1  Comparison of the literature number of sites and the number 
estimated by the model
Correctly estimated numbers of sites are shown in bold




1 25 1 0 26
2 5 9 0 14
3 0 4 7 11
Total 30 14 7 51
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Table 2  Probability of different numbers of protonation sites, estimated number of protonation sites and literature number of protonation sites 
for 51 resonances from 32 metabolites in human urine
Metabolite Database ID Chemical shift 
at pH7.4





Hydroxyisobutyrate HMDB0000729 1.347 91.893 7.488 0.619 1 1
Hydroxyisovalerate HMDB0000754 1.260 86.597 12.795 0.608 1 1
Indoxyl HMDB0004094 7.192 93.017 5.688 1.295 1 1
Methyl-2-oxovalerate HMDB0000695 1.093 95.383 4.326 0.291 1 1
Acetate HMDB0000042 1.910 93.326 5.879 0.795 1 1
Alanine HMDB0000161 1.212 0 80.827 19.173 2 2
Allantoin HMDB0000462 5.383 97.868 2.049 0.083 1 1
Citrate HMDB0000094 2.528 0 75.404 24.596 2 3
Citrate HMDB0000094 2.646 0 47.869 52.131 3 3
Creatinine HMDB0000562 3.033 87.889 11.593 0.518 1 2
Creatinine HMDB0000562 4.043 94.992 4.65 0.358 1 2
Formate HMDB0000142 8.448 92.786 6.377 0.837 1 1
Glucose HMDB0000122 5.228 98.661 1.284 0.055 1 1
Hippurate HMDB0000714 3.960 70.111 27.403 2.486 1 1
Hippurate HMDB0000714 7.541 86.036 9.798 4.166 1 1
Hippurate HMDB0000714 7.627 92.742 6.114 1.144 1 1
Hippurate HMDB0000714 7.824 92.264 5.387 2.349 1 1
Hippurate HMDB0000714 8.512 54.082 26.841 19.077 1 1
Histidine HMDB0000177 7.253 0 42.669 57.331 3 3
Histidine HMDB0000177 8.188 0 7.55 92.45 3 3
Imidazole HMDB0001525 7.229 59.201 37.952 2.847 1 1
Imidazole HMDB0001525 8.040 0 73.582 26.418 2 1
Isoleucine HMDB0000172 0.902 0.801 65.964 33.235 2 2
Lactate HMDB0000190 1.320 89.155 9.941 0.904 1 1
Leucine HMDB0000687 0.932 83.263 14.099 2.638 1 2
Mannitol HMDB0000765 3.673 92.487 6.501 1.012 1 1
Mannitol HMDB0000765 3.797 96.633 2.676 0.691 1 1
Mannitol HMDB0000765 3.864 96.567 2.964 0.469 1 1
Methylsuccinate HMDB0001844 1.062 43.561 50.274 6.165 2 2
Piperazine HMDB0014730 3.526 0 65.255 34.745 2 2
TMethylHistidine HMDB0000479 6.873 0 14.792 85.208 3 3
TMethylHistidine HMDB0000479 8.306 0 0 100 3 3
TTMethylHistidine HMDB0000001 3.788 0 94.773 5.227 2 3
TTMethylHistidine HMDB0000001 6.909 0 16.988 83.012 3 3
TTMethylHistidine HMDB0000001 8.396 0 23.514 76.486 3 3
Tartrate HMDB0029878 4.322 5.764 51.864 42.372 2 2
Taurine HMDB0000251 3.412 86.863 7.137 6 1 2
Threonine HMDB0000167 1.194 14.472 67.882 17.646 2 2
Trigonelline HMDB0000875 4.429 68.693 19.481 11.826 1 1
Trigonelline HMDB0000875 8.073 74.875 17.025 8.1 1 1
Trigonelline HMDB0000875 8.822 77.588 15.531 6.881 1 1
Trigonelline HMDB0000875 8.834 58.857 30.807 10.336 1 1
Trigonelline HMDB0000875 9.115 67.411 21.353 11.236 1 1
Tris CHEBI:9754 3.715 94.453 5.363 0.184 1 1
Tryptophan HMDB0000929 7.719 87.38 11.156 1.464 1 2
Tyrosine HMDB0000158 6.885 0 90.202 9.798 2 3
Tyrosine HMDB0000158 7.207 0 90.592 9.408 2 3
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Rows with correctly estimated numbers of sites are shown in bold
Table 2  (continued)
Metabolite Database ID Chemical shift 
at pH7.4





Valine HMDB0000883 0.906 0 79.851 20.149 2 2
Valine HMDB0000883 1.060 2.967 77.568 19.465 2 2
Xylose HMDB0000098 5.190 98.475 1.476 0.049 1 1
Trans-aconitate HMDB0000958 6.574 0 64.477 35.523 2 2
Table 3  Literature and 
modelled results of acetate, 
alanine, threonine and 
TTMethylHistidine
Metabolite Literature pKa values Modelled pKa values Modelled acid and base limits
Acetate 4.760 4.591 1.910 2.089
Alanine 2.340 9.690 2.384 9.980 1.212 1.472 1.573
Threonine 2.630 10.430 2.072 9.195 1.194 1.322 1.379
TTMethylHistidine 1.690 6.480 8.850 1.832 6.062 9.302 6.910 7.040 7.390 7.491
Fig. 2  Measured chemical shift changes for acetate, alanine, threonine and TTMethylHistidine with the fit of the theoretical model
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4.75. A third type of incorrect estmate happens when the 
change of chemical shift is too small so that the transition 
can not be detected near the pKa value, for instance creati-
nine as shown in Fig. 3. Conversely, the change in the chemi-
cal shift can be too large compared to the estimated meas-
urement error, for example imidazole as shown in Fig. 3, 
forming a fourth type of inaccuracy.
Some molecules have multiple resonances and so the 
question arises of whether to combine them, or if not, how 
to pick the best resonance to model. We do not recommend 
to combine resonances from the same molecule as, with our 
data, this tended to over estimate the number of protonation 
sites leading to a poorer fit. Instead, it is preferred to pick 
a resonance with “good behaviour”, i.e. one which is not 
overlapped, shows strong changes in chemical shift, but with 
a good number of observations near each chemical shift tran-
sition (near the pKa). When more than one resonance from 
the same molecule are modelled and give different predic-
tions for the number of sites, we recommend to use informa-
tion such as the model fit error to judge which estimation 
is more reliable. We note that this does not apply in fully 
untargeted analysis when the metabolites are unidentified, 
and thus one does not know if two resonances come from 
the same molecule.
4  Conclusions
The Bayesian fit based on the model of Szakács et al. (2004) 
can effectively estimate the number of protonation sites for 
many small molecule metabolites, given sufficient pH titra-
tion data. Incorrect estimations are mainly due to cases 
where pKa values are very similar, and thus could not be dis-
tinguished, and/or a lack of data in the necessary pH ranges. 
We note that, even when the number of sites was incor-
rectly estimated, it is still possible to estimate the chemi-
cal shift position of a resonance quite accurately in most 
cases. The information obtained from the modelling pro-
cedure described here could be useful in a number of ways. 
For example, the pH could be estimated from the positions 
of a few well known and easily located resonances. This 
could then be used to predict the chemical shift positions of 
Fig. 3  Examples of resonances with incorrectly estimated numbers of sites: taurine, citrate, creatinine, imidazole with literature pKa values (yel-
low line) and fitted pKa values (green line)
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resonances of other metabolites expected in a sample, which 
could then help with automated annotation, alignment or 
peak fitting (as an initial position estimate). The predicted 
number of protonation sites may also be helpful during 
the process of identifying unknown compounds, although 
orthogonal analytical information would almost always be 
needed in addition. Overall, we hope that this modelling 
approach may be valuable for the future development of 
algorithms for analysis of metabolomic 1 H NMR spectra 
including alignment, annotation and peak fitting.
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